A recent study published in The Lancet highlights the effectiveness of the human papillomavirus (HPV) vaccine in preventing cervical cancer, reporting that girls vaccinated at age 12 or 13 had an almost negligible risk of dying from cervical cancer before turning 30. The finding reinforces the significance of the NHS’s ongoing HPV vaccination programme aimed at reducing the incidence of cervical and other HPV-related cancers in the UK.

Cervical cancer, although less common than other cancer types, still results in approximately 880 deaths annually in the UK. The primary cause of cervical cancer is persistent infection with high-risk HPV types, which can lead to cancer many years after initial infection. HPV is highly prevalent and is most commonly transmitted through skin-to-skin contact, including sexual activity. In many cases, infection resolves spontaneously without symptoms, but when persistent, it may cause cellular changes that develop into cancer. Besides cervical cancer, HPV infection is also linked to cancers of the mouth, throat, anus, penis, vulva, and vagina, as well as to non-cancerous genital warts.

Since 2008, the NHS has offered the HPV vaccine free to all children in Year 8, typically aged 12 or 13, prioritizing vaccination before potential exposure to the virus. The programme expanded in 2019 to include boys, recognizing that HPV affects both sexes and that vaccinating boys reduces overall virus transmission. Most individuals gain strong protection from a single dose, though catch-up vaccination remains available free of charge up to the age of 25, particularly important for those who missed vaccination in school. The vaccine is also recommended for higher-risk groups such as people living with HIV.

The HPV vaccines do not contain live virus and thus cannot cause HPV infection. They function by stimulating the immune system to recognize and combat the virus upon future exposure. Side effects are generally mild and temporary, with the most common reactions being soreness or swelling at the injection site, alongside occasional headache or mild fever. Serious adverse effects are extremely rare, and the vaccine maintains a strong safety record.

Since the introduction of the vaccination programme, infection rates among young people have dropped significantly, contributing to a recent measurable decline in cervical cancer cases, especially in those vaccinated at the recommended age. This progress is bolstered by complementary cervical screening programmes, which remain crucial as the vaccine does not protect against all HPV types capable of causing cervical cancer. Women are advised to continue attending screening appointments for early detection of precancerous changes.

Despite these advances, vaccine uptake varies across communities, with some parents expressing safety concerns or lacking comprehensive information about HPV. Additionally, some children miss vaccination opportunities due to school absences. Ensuring clear communication and accessible catch-up vaccinations is vital to sustaining high coverage rates.

The NHS’s broader goal is to eliminate cervical cancer in England by 2040, leveraging both vaccination and cervical screening as key preventative measures. The success of the HPV vaccination programme not only protects vaccinated individuals but also reduces HPV prevalence in the population, indirectly safeguarding those unvaccinated or in whom the vaccine is less effective. As uptake improves, the burden of HPV-related cancers is expected to decline further, offering substantial public health benefits in the coming decades.